{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:37:40Z","timestamp":1761061060769},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T00:00:00Z","timestamp":1592006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T00:00:00Z","timestamp":1592006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Deletions of 17p13 recurrently occur in renal cell carcinoma (RCC) but their prognostic role seems to be uncertain.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To determine prevalence, relationship with tumor phenotype, and patient prognosis, a tissue microarray containing samples from 1809 RCCs was evaluated using dual labeling fluorescence in situ hybridization (FISH) with 17p13 and chromosome 17 centromere probes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A 17p13 deletion was found in 72 of 1429 interpretable tumors. The frequency of 17p13 deletions varied greatly between RCC subtypes and was highest in chromophobe RCC (24\/72; 33.3%). 17p13 deletions were also found in 35 (3.7%) of 946 clear cell RCC, 9 (4.3%) of 208 papillary RCC, 1 of 121 oncocytomas (0.8%), as well as in several rare cases of comprising 1 of 7 Xp11.2 translocation cancers, 1 of 3 collecting duct carcinomas, and 1 of 20 not otherwise specified (NOS) carcinomas. In clear cell carcinomas, 17p13 deletions revealed a strong and consistent association with higher Fuhrman, ISUP, and Thoenes grade (<jats:italic>p<\/jats:italic> &lt; 0.0001 each), and linked to advanced tumor stage (<jats:italic>p<\/jats:italic> = 0.0168), large tumor diameter (<jats:italic>p<\/jats:italic> = 0.0004), distant metastases (<jats:italic>p<\/jats:italic> = 0.0077), cancer-specific survival (<jats:italic>p<\/jats:italic> = 0.0391), and recurrence-free survival (<jats:italic>p<\/jats:italic> = 0.0072). In multivariate analysis, 17p13 deletions showed in clear cell RCC a dependent prognostic role for established clinical-pathological parameters.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>17p13 deletions have a dual role in RCC. They are associated with disease progression in clear cell RCC and possibly other subtypes and they are linked to the development of chromophobe RCC\u2014a subtype with a particularly favorable prognosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12957-020-01902-y","type":"journal-article","created":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T20:02:34Z","timestamp":1592078554000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chromosome 17p13 deletion is associated with an aggressive tumor phenotype in clear cell renal cell carcinoma"],"prefix":"10.1186","volume":"18","author":[{"given":"Till","family":"Eichenauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navid","family":"Shadanpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Kluth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cosima","family":"G\u00f6bel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f6ren","family":"Weidemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Fraune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"B\u00fcscheck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Hube-Magg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"M\u00f6ller-Koop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Dahlem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margit","family":"Fisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Riechardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eike","family":"Burandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Bernreuther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Minner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waldemar","family":"Wilczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Till","family":"Clauditz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,13]]},"reference":[{"key":"1902_CR1","doi-asserted-by":"publisher","first-page":"g4797","DOI":"10.1136\/bmj.g4797","volume":"349","author":"E Jonasch","year":"2014","unstructured":"Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. 2014;349:g4797.","journal-title":"BMJ"},{"key":"1902_CR2","doi-asserted-by":"publisher","first-page":"15698","DOI":"10.1038\/s41598-017-15922-4","volume":"7","author":"MCS Wong","year":"2017","unstructured":"Wong MCS, Goggins WB, Yip BHK, Fung FDH, Leung C, Fang Y, Wong SYS, Ng CF. Incidence and mortality of kidney cancer: temporal patterns and global trends in 39 countries. Sci Rep. 2017;7:15698.","journal-title":"Sci Rep"},{"key":"1902_CR3","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s00345-018-2286-7","volume":"36","author":"SH Rossi","year":"2018","unstructured":"Rossi SH, Klatte T, Usher-Smith J, Stewart GD. Epidemiology and screening for renal cancer. World J Urol. 2018;36:1341\u201353.","journal-title":"World J Urol"},{"key":"1902_CR4","doi-asserted-by":"crossref","unstructured":"Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernandez-Pello S, Giles RH, Hofmann F, Hora M, Kuczyk MA, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur Urol. 2019(75):799\u2013810.","DOI":"10.1016\/j.eururo.2019.02.011"},{"key":"1902_CR5","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthelemy P, Porta C, George S, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277\u201390.","journal-title":"N Engl J Med"},{"key":"1902_CR6","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","volume":"35","author":"TK Choueiri","year":"2017","unstructured":"Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olencki T, Picus J, Small EJ, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017;35:591\u20137.","journal-title":"J Clin Oncol"},{"key":"1902_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"1902_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/978-981-13-0593-1_9","volume":"1044","author":"M Chen","year":"2018","unstructured":"Chen M, Yang Y, Liu Y, Chen C. The role of chromosome deletions in human cancers. Adv Exp Med Biol. 2018;1044:135\u201348.","journal-title":"Adv Exp Med Biol"},{"key":"1902_CR9","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1002\/ijc.29613","volume":"137","author":"M Kluth","year":"2015","unstructured":"Kluth M, Runte F, Barow P, Omari J, Abdelaziz ZM, Paustian L, Steurer S, Christina Tsourlakis M, Fisch M, Graefen M, et al. Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer. Int J Cancer. 2015;137:2354\u201363.","journal-title":"Int J Cancer"},{"key":"1902_CR10","doi-asserted-by":"publisher","first-page":"81322","DOI":"10.18632\/oncotarget.13227","volume":"7","author":"P Lebok","year":"2016","unstructured":"Lebok P, Roming M, Kluth M, Koop C, Ozden C, Taskin B, Hussein K, Lebeau A, Witzel I, Wolber L, et al. p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer. Oncotarget. 2016;7:81322\u201331.","journal-title":"Oncotarget"},{"key":"1902_CR11","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.humpath.2012.12.006","volume":"44","author":"BA Bohn","year":"2013","unstructured":"Bohn BA, Mina S, Krohn A, Simon R, Kluth M, Harasimowicz S, Quaas A, Bockhorn M, Izbicki JR, Sauter G, et al. Altered PTEN function caused by deletion or gene disruption is associated with poor prognosis in rectal but not in colon cancer. Hum Pathol. 2013;44:1524\u201333.","journal-title":"Hum Pathol"},{"key":"1902_CR12","first-page":"4514","volume":"61","author":"R Simon","year":"2001","unstructured":"Simon R, Richter J, Wagner U, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knonagel H, et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res. 2001;61:4514\u20139.","journal-title":"Cancer Res"},{"key":"1902_CR13","first-page":"356","volume":"145","author":"MR Speicher","year":"1994","unstructured":"Speicher MR, Schoell B, du Manoir S, Schrock E, Ried T, Cremer T, Storkel S, Kovacs A, Kovacs G. Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol. 1994;145:356\u201364.","journal-title":"Am J Pathol"},{"key":"1902_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1309\/AJCPSATJTKBI6J4N","volume":"133","author":"M Brunelli","year":"2010","unstructured":"Brunelli M, Delahunt B, Gobbo S, Tardanico R, Eccher A, Bersani S, Cossu-Rocca P, Parolini C, Balzarini P, Menestrina F, et al. Diagnostic usefulness of fluorescent cytogenetics in differentiating chromophobe renal cell carcinoma from renal oncocytoma: a validation study combining metaphase and interphase analyses. Am J Clin Pathol. 2010;133:116\u201326.","journal-title":"Am J Clin Pathol"},{"key":"1902_CR15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1471-2407-9-152","volume":"9","author":"MV Yusenko","year":"2009","unstructured":"Yusenko MV, Kuiper RP, Boethe T, Ljungberg B, van Kessel AG, Kovacs G. High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas. BMC Cancer. 2009;9:152.","journal-title":"BMC Cancer"},{"key":"1902_CR16","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/j.1365-2559.2004.01884.x","volume":"44","author":"A Nagy","year":"2004","unstructured":"Nagy A, Buzogany I, Kovacs G. Microsatellite allelotyping differentiates chromophobe renal cell carcinomas from renal oncocytomas and identifies new genetic changes. Histopathology. 2004;44:542\u20136.","journal-title":"Histopathology"},{"key":"1902_CR17","doi-asserted-by":"crossref","unstructured":"Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM: The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol 2016, 70:93-105.","DOI":"10.1016\/j.eururo.2016.02.029"},{"key":"1902_CR18","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00345-011-0783-z","volume":"31","author":"C Eichelberg","year":"2013","unstructured":"Eichelberg C, Minner S, Isbarn H, Burandt E, Terracciano L, Moch H, Kell A, Heuer R, Chun FK, Sauter G, et al. Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma. World J Urol. 2013;31:847\u201353.","journal-title":"World J Urol"},{"key":"1902_CR19","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/nm0798-844","volume":"4","author":"J Kononen","year":"1998","unstructured":"Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844\u20137.","journal-title":"Nat Med"},{"key":"1902_CR20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.18632\/oncotarget.13425","volume":"8","author":"M Kluth","year":"2017","unstructured":"Kluth M, Amschler NN, Galal R, Moller-Koop C, Barrow P, Tsourlakis MC, Jacobsen F, Hinsch A, Wittmer C, Steurer S, et al. Deletion of 8p is an independent prognostic parameter in prostate cancer. Oncotarget. 2017;8:379\u201392.","journal-title":"Oncotarget"},{"key":"1902_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ajpath.2012.04.026","volume":"181","author":"A Krohn","year":"2012","unstructured":"Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Kornblum M, Kotschau D, Tennstedt P, Huang J, Gerhauser C, et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. The American journal of pathology. 2012;181:401\u201312.","journal-title":"The American journal of pathology"},{"key":"1902_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000056987","volume":"93","author":"D Reutzel","year":"2001","unstructured":"Reutzel D, Mende M, Naumann S, Storkel S, Brenner W, Zabel B, Decker J. Genomic imbalances in 61 renal cancers from the proximal tubulus detected by comparative genomic hybridization. Cytogenet Cell Genet. 2001;93:221\u20137.","journal-title":"Cytogenet Cell Genet"},{"key":"1902_CR23","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/(SICI)1096-9896(199902)187:3<308::AID-PATH256>3.0.CO;2-E","volume":"187","author":"J Gronwald","year":"1999","unstructured":"Gronwald J, Baur AS, Holtgreve-Grez H, Jauch A, Mosimann F, Jichlinski P, Wauters JP, Cremer T, Guillou L. Chromosomal abnormalities in renal cell neoplasms associated with acquired renal cystic disease. A series studied by comparative genomic hybridization and fluorescence in situ hybridization. J Pathol. 1999;187:308\u201312.","journal-title":"J Pathol"},{"key":"1902_CR24","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/(SICI)1096-9896(199702)181:2<136::AID-PATH766>3.0.CO;2-2","volume":"181","author":"H Contractor","year":"1997","unstructured":"Contractor H, Zariwala M, Bugert P, Zeisler J, Kovacs G. Mutation of the p53 tumour suppressor gene occurs preferentially in the chromophobe type of renal cell tumour. J Pathol. 1997;181:136\u20139.","journal-title":"J Pathol"},{"key":"1902_CR25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/path.1711670303","volume":"167","author":"A Kovacs","year":"1992","unstructured":"Kovacs A, Storkel S, Thoenes W, Kovacs G. Mitochondrial and chromosomal DNA alterations in human chromophobe renal cell carcinomas. J Pathol. 1992;167:273\u20137.","journal-title":"J Pathol"},{"key":"1902_CR26","first-page":"3092","volume":"53","author":"RE Reiter","year":"1993","unstructured":"Reiter RE, Anglard P, Liu S, Gnarra JR, Linehan WM. Chromosome 17p deletions and p53 mutations in renal cell carcinoma. Cancer Res. 1993;53:3092\u20137.","journal-title":"Cancer Res"},{"key":"1902_CR27","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1073\/pnas.1525735113","volume":"113","author":"M Bi","year":"2016","unstructured":"Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, et al. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proc Natl Acad Sci U S A. 2016;113:2170\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1902_CR28","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/BF00192279","volume":"12","author":"H Brauch","year":"1994","unstructured":"Brauch H, Pomer S, Hieronymus T, Schadt T, Lohrke H, Komitowski D. Genetic alterations in sporadic renal-cell carcinoma: molecular analyses of tumor suppressor gene harboring chromosomal regions 3p, 5q, and 17p. World J Urol. 1994;12:162\u20138.","journal-title":"World J Urol"},{"key":"1902_CR29","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/ijc.2910640609","volume":"64","author":"MA Kuczyk","year":"1995","unstructured":"Kuczyk MA, Serth J, Bokemeyer C, Jonassen J, Arndt H, Paeslack U, Werner M, Tan HK, Jonas U. Detection of p53 gene alteration in renal-cell cancer by micropreparation techniques of tumor specimens. Int J Cancer. 1995;64:399\u2013406.","journal-title":"Int J Cancer"},{"key":"1902_CR30","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/S0022-5347(17)35764-6","volume":"150","author":"T Uchida","year":"1993","unstructured":"Uchida T, Wada C, Shitara T, Egawa S, Mashimo S, Koshiba K. Infrequent involvement of p53 mutations and loss of heterozygosity of 17p in the tumorigenesis of renal cell carcinoma. J Urol. 1993;150:1298\u2013301.","journal-title":"J Urol"},{"key":"1902_CR31","first-page":"923","volume":"5","author":"F Fogt","year":"1998","unstructured":"Fogt F, Zhuang Z, Linehan WM, Merino MJ. Collecting duct carcinomas of the kidney: a comparative loss of heterozygosity study with clear cell renal cell carcinoma. Oncol Rep. 1998;5:923\u20136.","journal-title":"Oncol Rep"},{"key":"1902_CR32","first-page":"820","volume":"51","author":"R Morita","year":"1991","unstructured":"Morita R, Ishikawa J, Tsutsumi M, Hikiji K, Tsukada Y, Kamidono S, Maeda S, Nakamura Y. Allelotype of renal cell carcinoma. Cancer Res. 1991;51:820\u20133.","journal-title":"Cancer Res"},{"key":"1902_CR33","first-page":"1881","volume":"52","author":"O Ogawa","year":"1992","unstructured":"Ogawa O, Habuchi T, Kakehi Y, Koshiba M, Sugiyama T, Yoshida O. Allelic losses at chromosome 17p in human renal cell carcinoma are inversely related to allelic losses at chromosome 3p. Cancer Res. 1992;52:1881\u20135.","journal-title":"Cancer Res"},{"key":"1902_CR34","first-page":"1544","volume":"51","author":"JC Presti Jr","year":"1991","unstructured":"Presti JC Jr, Rao PH, Chen Q, Reuter VE, Li FP, Fair WR, Jhanwar SC. Histopathological, cytogenetic, and molecular characterization of renal cortical tumors. Cancer Res. 1991;51:1544\u201352.","journal-title":"Cancer Res"},{"key":"1902_CR35","first-page":"5780","volume":"53","author":"JC Presti Jr","year":"1993","unstructured":"Presti JC Jr, Reuter VE, Cordon-Cardo C, Mazumdar M, Fair WR, Jhanwar SC. Allelic deletions in renal tumors: histopathological correlations. Cancer Res. 1993;53:5780\u20133.","journal-title":"Cancer Res"},{"key":"1902_CR36","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/bjc.1994.44","volume":"69","author":"K Foster","year":"1994","unstructured":"Foster K, Crossey PA, Cairns P, Hetherington JW, Richards FM, Jones MH, Bentley E, Affara NA, Ferguson-Smith MA, Maher ER. Molecular genetic investigation of sporadic renal cell carcinoma: analysis of allele loss on chromosomes 3p, 5q, 11p, 17 and 22. Br J Cancer. 1994;69:230\u20134.","journal-title":"Br J Cancer"},{"key":"1902_CR37","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/gcc.1129","volume":"31","author":"M Hoglund","year":"2001","unstructured":"Hoglund M, Gisselsson D, Mandahl N, Johansson B, Mertens F, Mitelman F, Sall T. Multivariate analyses of genomic imbalances in solid tumors reveal distinct and converging pathways of karyotypic evolution. Genes Chromosomes Cancer. 2001;31:156\u201371.","journal-title":"Genes Chromosomes Cancer"},{"key":"1902_CR38","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/ijc.24642","volume":"125","author":"M Chen","year":"2009","unstructured":"Chen M, Ye Y, Yang H, Tamboli P, Matin S, Tannir NM, Wood CG, Gu J, Wu X. Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer. 2009;125:2342\u20138.","journal-title":"Int J Cancer"},{"key":"1902_CR39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1440-1827.1997.tb03724.x","volume":"47","author":"J Sugimura","year":"1997","unstructured":"Sugimura J, Tamura G, Suzuki Y, Fujioka T. Allelic loss on chromosomes 3p, 5q and 17p in renal cell carcinomas. Pathol Int. 1997;47:79\u201383.","journal-title":"Pathol Int"},{"key":"1902_CR40","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1073\/pnas.92.7.2854","volume":"92","author":"CA Thrash-Bingham","year":"1995","unstructured":"Thrash-Bingham CA, Greenberg RE, Howard S, Bruzel A, Bremer M, Goll A, Salazar H, Freed JJ, Tartof KD. Comprehensive allelotyping of human renal cell carcinomas using microsatellite DNA probes. Proc Natl Acad Sci U S A. 1995;92:2854\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1902_CR41","first-page":"5817","volume":"51","author":"R Morita","year":"1991","unstructured":"Morita R, Saito S, Ishikawa J, Ogawa O, Yoshida O, Yamakawa K, Nakamura Y. Common regions of deletion on chromosomes 5q, 6q, and 10q in renal cell carcinoma. Cancer Res. 1991;51:5817\u201320.","journal-title":"Cancer Res"},{"key":"1902_CR42","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1158\/1078-0432.CCR-12-3825","volume":"19","author":"GG Malouf","year":"2013","unstructured":"Malouf GG, Monzon FA, Couturier J, Molinie V, Escudier B, Camparo P, Su X, Yao H, Tamboli P, Lopez-Terrada D, et al. Genomic heterogeneity of translocation renal cell carcinoma. Clin Cancer Res. 2013;19:4673\u201384.","journal-title":"Clin Cancer Res"},{"key":"1902_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.humpath.2014.09.001","volume":"46","author":"CM Perrino","year":"2015","unstructured":"Perrino CM, Hucthagowder V, Evenson M, Kulkarni S, Humphrey PA. Genetic alterations in renal cell carcinoma with rhabdoid differentiation. Hum Pathol. 2015;46:9\u201316.","journal-title":"Hum Pathol"},{"key":"1902_CR44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/(SICI)1097-0215(19960927)68:1<47::AID-IJC9>3.0.CO;2-X","volume":"68","author":"T Dijkhuizen","year":"1996","unstructured":"Dijkhuizen T, Van den Berg E, Van den Berg A, Storkel S, De Jong B, Seitz G, Henn W. Chromosomal findings and p53-mutation analysis in chromophilic renal-cell carcinomas. Int J Cancer. 1996;68:47\u201350.","journal-title":"Int J Cancer"},{"key":"1902_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1089\/109153601750124221","volume":"5","author":"K Yoshioka","year":"2001","unstructured":"Yoshioka K, Nakamura S. Chromosome 9 and 17 aberrations and p53 gene deletion detected by fluorescence in situ hybridization in renal-cell carcinoma. Mol Urol. 2001;5:11\u20137.","journal-title":"Mol Urol"},{"key":"1902_CR46","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00432-018-2817-z","volume":"145","author":"VD Li","year":"2019","unstructured":"Li VD, Li KH, Li JT. TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database. J Cancer Res Clin Oncol. 2019;145:625\u201336.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1902_CR47","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/cncr.27947","volume":"119","author":"N Kroeger","year":"2013","unstructured":"Kroeger N, Klatte T, Chamie K, Rao PN, Birkhauser FD, Sonn GA, Riss J, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma. Cancer. 2013;119:1547\u201354.","journal-title":"Cancer"},{"key":"1902_CR48","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/modpathol.2011.107","volume":"24","author":"FA Monzon","year":"2011","unstructured":"Monzon FA, Alvarez K, Peterson L, Truong L, Amato RJ, Hernandez-McClain J, Tannir N, Parwani AV, Jonasch E. Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. Mod Pathol. 2011;24:1470\u20139.","journal-title":"Mod Pathol"},{"key":"1902_CR49","doi-asserted-by":"publisher","first-page":"43 e13","DOI":"10.1016\/j.urolonc.2019.09.024","volume":"38","author":"T Eichenauer","year":"2020","unstructured":"Eichenauer T, Bannenberg DC, Kluth M, Wittmer C, Buscheck F, Moller K, Dum D, Fraune C, Hube-Magg C, Moller-Koop C, et al. 8p deletions in renal cell carcinoma are associated with unfavorable tumor features and poor overall survival. Urol Oncol. 2020;38:43 e13\u201320.","journal-title":"Urol Oncol"},{"issue":"6","key":"1902_CR50","doi-asserted-by":"publisher","first-page":"605.e1","DOI":"10.1016\/j.urolonc.2020.02.022","volume":"38","author":"T Eichenauer","year":"2020","unstructured":"Eichenauer T, Simmendinger L, Kluth M, Chirico V, Luebke AM, Hoflmayer D, Hinsch A, Jacobsen F, Hube-Magg C, Moller-Koop C, et al. Chromosomal deletion of 9p21 is linked to poor patient prognosis in papillary and clear cell kidney cancer. Urol Oncol. 2020;38(6):605.e1.","journal-title":"Urol Oncol"},{"key":"1902_CR51","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.ajpath.2013.01.007","volume":"182","author":"Z Lichner","year":"2013","unstructured":"Lichner Z, Scorilas A, White NM, Girgis AH, Rotstein L, Wiegand KC, Latif A, Chow C, Huntsman D, Yousef GM. The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma. Am J Pathol. 2013;182:1163\u201370.","journal-title":"Am J Pathol"},{"key":"1902_CR52","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.urolonc.2013.12.008","volume":"32","author":"D de Oliveira","year":"2014","unstructured":"de Oliveira D, Dall'Oglio MF, Reis ST, Zerati M, Souza IC, Leite KR, Srougi M. Chromosome 9p deletions are an independent predictor of tumor progression following nephrectomy in patients with localized clear cell renal cell carcinoma. Urol Oncol. 2014;32:601\u20136.","journal-title":"Urol Oncol"},{"key":"1902_CR53","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0002-9440(10)65734-3","volume":"153","author":"F Jiang","year":"1998","unstructured":"Jiang F, Richter J, Schraml P, Bubendorf L, Gasser T, Sauter G, Mihatsch MJ, Moch H. Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am J Pathol. 1998;153:1467\u201373.","journal-title":"Am J Pathol"},{"key":"1902_CR54","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1200\/JCO.2007.15.8345","volume":"27","author":"T Klatte","year":"2009","unstructured":"Klatte T, Rao PN, de Martino M, LaRochelle J, Shuch B, Zomorodian N, Said J, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol. 2009;27:746\u201353.","journal-title":"J Clin Oncol"},{"key":"1902_CR55","first-page":"476508","volume":"2015","author":"NY Yap","year":"2015","unstructured":"Yap NY, Rajandram R, Ng KL, Pailoor J, Fadzli A, Gobe GC. Genetic and chromosomal aberrations and their clinical significance in renal neoplasms. Biomed Res Int. 2015;2015:476508.","journal-title":"Biomed Res Int"},{"key":"1902_CR56","doi-asserted-by":"crossref","unstructured":"Buscheck F, Fraune C, Kluth M, Lennartz M, Simon R, Hube-Magg C, Morlock C, Barbieri S, Wahl C, Eichelberg C, et al. A non-diploid DNA status is linked to poor prognosis in renal cell cancer. World J Urol. 2020.","DOI":"10.1007\/s00345-020-03226-8"},{"key":"1902_CR57","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41467-018-08020-0","volume":"10","author":"J Mathieu","year":"2019","unstructured":"Mathieu J, Detraux D, Kuppers D, Wang Y, Cavanaugh C, Sidhu S, Levy S, Robitaille AM, Ferreccio A, Bottorff T, et al. Folliculin regulates mTORC1\/2 and WNT pathways in early human pluripotency. Nat Commun. 2019;10:632.","journal-title":"Nat Commun"},{"key":"1902_CR58","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1097\/00000478-200212000-00002","volume":"26","author":"CP Pavlovich","year":"2002","unstructured":"Pavlovich CP, Walther MM, Eyler RA, Hewitt SM, Zbar B, Linehan WM, Merino MJ. Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol. 2002;26:1542\u201352.","journal-title":"Am J Surg Pathol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-020-01902-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-020-01902-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-020-01902-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T23:08:42Z","timestamp":1623539322000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-020-01902-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,13]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1902"],"URL":"https:\/\/doi.org\/10.1186\/s12957-020-01902-y","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,13]]},"assertion":[{"value":"15 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the ethics committee \u00c4rztekammer Hamburg (WF-049\/09). The work has been carried out in compliance with the Helsinki Declaration. Informed consent: According to local laws (HmbKHG, \u00a712,1), informed consent was not necessary.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No individual person\u2019s data have been used in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}